IperionX Runs Its Virginia Plant Around the Clock While Revenue Stays at Zero

IperionX scaled titanium powder capacity to about 200 tonnes a year, but fiscal 2026 revenue was zero and its net loss nearly doubled to USD 66.8 million.

Scaling a metallurgical process from lab bench to industrial output is the most unforgiving stretch in a young manufacturer's life. IperionX is currently living through that stretch in full public view, and the numbers for fiscal 2026 lay out both sides of the bargain.

On the plant floor, the company has plenty to point to. Operations in the US state of Virginia were moved to a continuous schedule — seven days a week, around the clock. At the same time, nominal capacity for titanium powder production rose from 125 tonnes to roughly 200 tonnes per year. Management is aiming for an annualized output rate of about 200 tonnes by the end of calendar 2026, and the infrastructure is now in place to handle larger volumes.

A Full Shift Calendar, an Empty Revenue Line

Commercial traction, however, has not kept pace with the technical buildout. The filed annual report shows no revenue at all for fiscal 2026. Every dollar of operating expense is therefore running without a matching customer invoice behind it.

That mismatch hits the bottom line hard. The net loss nearly doubled, from USD 35.3 million in fiscal 2025 to USD 66.8 million in fiscal 2026. Net cash outflows from operating activities and investments totaled USD 63.5 million over the past fiscal year — a steady drain that no sales are yet offsetting.

The Next Step Up Comes With a Price Tag

The real test still lies ahead. For 2027, IperionX is planning another capacity leap, to roughly 1,400 tonnes per year. Management puts the estimated capital expenditure for that expansion at around USD 75 million. A plant running continuously incurs ongoing costs for staff, materials and energy, so the pace of the buildout effectively dictates the company's financial risk.

Analysts have taken note. On 30 September, B. Riley Securities cut its price target on the stock from USD 52 to USD 34, while keeping its "Buy" rating. The firm tied the revision explicitly to the higher net loss in the second half of 2026 and to unexpectedly large research and development spending. The retained recommendation signals continued confidence in the market potential, but the rising development costs also show how expensive it is in practice to establish new metallurgical processes — and how much they raise the risk of future capital measures.

Market Patience Wears Thin

The combination of zero revenue and heavy cash burn has kept investors cautious. The shares closed Monday at EUR 1.53, down 51 percent since the start of the year.

IperionX thus stands at a crossroads. The technical scaling and the shift to continuous production argue for the technological feasibility of the approach. But manufacturing cannot remain an end in itself. As long as the revenue line reads zero, every expansion step increases the financial exposure — and the planned USD 75 million investment leaves little room for delays. Anyone holding the stock is betting that the ambitious 2027 capacity targets translate into real income quickly. Until dependable commercial revenue starts flowing, the fundamental risks of this costly expansion course dominate the picture.